Adaptimmune price target lowered to $1.75 from $3 at Guggenheim
Guggenheim lowered the firm’s price target on Adaptimmune (ADAP) to $1.75 from $3 and keeps a Buy rating on the shares. The firm is updating ...
Adaptimmune price target lowered to $1.50 from $2 at Wells Fargo
Wells Fargo lowered the firm’s price target on Adaptimmune (ADAP) to $1.50 from $2 and keeps an Equal Weight rating on the shares. Following Q4 ...
Yahoo Finance11d
Adaptimmune Provides Q4 and Full Year 2024 Business Update
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers ...
Benzinga.com5mon
Adaptimmune Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ADAP | Benzinga
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade FDA approves Adaptimmune Therapeutics' Tecelra ...